系统评价VEGFR-3在乳腺癌组织中的表达及其临床意义
|
摘要
目的系统评价乳腺癌患者癌变组织中血管内皮生长因子受体3(vascular endothelial growth factor receptor3,VEGFR-3)的表达情况,并分析其临床意义。方法以乳腺癌、VEGFR-3、VEGF-3为检索词,检索中国科技期刊全文数据库(VIP)、中国学术期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)和万方数据库,收集VEGFR-3在癌组织中的表达与乳腺癌的关系的相关文献,年限2012~2017年,对纳入的文献应用Stata14软件进行Meta分析。结果共纳入11个病例对照研究,共计1 222个病例。Meta分析结果显示,乳腺癌组与正常对照组、淋巴结转移阳性组与阴性组、肿瘤大小≤2 cm与>2 cm、临床Ⅰ~Ⅱ期与Ⅲ期之间VEGFR-3的表达水平比较差异均具有统计学意义(P<0.05)。结论 VEGFR-3表达与乳腺癌肿瘤大小、淋巴结有无转移、乳腺癌临床分期均显著相关,提示VEGFR-3可能参与乳腺癌的发生发展过程,并可能影响乳腺癌的预后效果。
Objective To systematically evaluate the expression of VEGFR-3 in the cancer tissues of breast cancer patients and then analyze its clinical significance. Methods The published documents on the relationship between VEGFR-3 expression in cancer tissues and breast cancer were collected by searching the CNKI,VIP,CBM and Wanfang database with breast cancer,VEGFR-3 and VEGF-3 as the key words.The retrieval year limit was from 2012 to 2017. The Stata14 software was applied to Meta-analysis on these documents. Results A total of 11 case-control studies including 1 222 cases were involved. Meta-analysis results showed that statistically significant differences of expression of VEGFR-3 were found between the breast cancer group and the control group,lymph node metastasis positive group and negative group,the tumor size ≤2 cm and >2 cm,and the clinical stageⅠ ~ Ⅱand Ⅲ( P<0.05). Conclusion The expression of VEGFR-3 is significantly correlated with the tumor size,lymph nodes metastasis,clinical staging of breast,suggesting that VEGFR-3 may participate in the occurrence and development of breast cancer and may affect the prognosis effect of breast cancer.
Objective To systematically evaluate the expression of VEGFR-3 in the cancer tissues of breast cancer patients and then analyze its clinical significance. Methods The published documents on the relationship between VEGFR-3 expression in cancer tissues and breast cancer were collected by searching the CNKI,VIP,CBM and Wanfang database with breast cancer,VEGFR-3 and VEGF-3 as the key words.The retrieval year limit was from 2012 to 2017. The Stata14 software was applied to Meta-analysis on these documents. Results A total of 11 case-control studies including 1 222 cases were involved. Meta-analysis results showed that statistically significant differences of expression of VEGFR-3 were found between the breast cancer group and the control group,lymph node metastasis positive group and negative group,the tumor size ≤2 cm and >2 cm,and the clinical stageⅠ ~ Ⅱand Ⅲ( P<0.05). Conclusion The expression of VEGFR-3 is significantly correlated with the tumor size,lymph nodes metastasis,clinical staging of breast,suggesting that VEGFR-3 may participate in the occurrence and development of breast cancer and may affect the prognosis effect of breast cancer.
引文
[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA:A Cancer Journal for Clinicians,2015,65(2):87-108.
[2]Cedolini C,Bertozzi S,Londero AP,et al.Type of breast cancer diagnosis,screening,and survival[J].Clinical breast cancer,2014,14(4):235-40.
[3]Yeh YW,Cheng CC,Yang ST,et al.Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling[J].Oncotarget,2017,8(3):5603-5618.
[4]Varney ML,Singh RK. VEGF-C-VEGFR3/Flt4 axis regulates mammary tumor growth and metastasis in an autocrine manner[J]. American Journal of Cancer Research,2015,5(2):616-628.
[5]单海琳,邵清. ADAM8和VEGFR-3在乳腺癌中的表达及意义[J].成都医学院学报,2012,7(4):582-585.
[6]宋新峰,路喜安.EGFR VEGFR-3 PDGFRa在三阴乳腺癌中的表达及其临床意义[J].中国药物与临床,2012,12(12):1560-1562.
[7]吴建忠,陈琳,周文斌,等.VEGF受体3在乳腺癌组织中的表达及其意义[J].中国修复重建外科杂志,2013,27(12):1487-1450.
[8]李志刚,黄桂林.青年乳腺癌VEGF-C和VEGFR-3的表达及其与临床病理关系的研究[J].临床和实验医学杂志,2012,11(11):821-822.
[9]刘新兰,黄英,陈萍.人乳腺球蛋白、血管内皮生长因子-C和血管内皮生长因子受体-3在乳腺癌中的表达及其与预后的关系[J].第二军医大学学报,2013,34(10):1078-1082.
[10]刘丽娜.乳腺癌VEGF-C和VEGFR-3表达与淋巴结转移关系[J].中国现代药物应用,2015,9(8):29-30.
[11]王官成,王立军,杨连祥.乳腺癌组织中血管内皮生长因子C、血管内皮生长因子受体3的表达及相关性研究[J].中国煤炭工业医学杂志,2013,16(8):1250-1253.
[12]陈润琦.乳腺癌血管内皮细胞生长因子-C及其受体-3的表达及临床作用[J].中国药物与临床,2013,13(4):496-497.
[13]赵云霞,马琳,蔡兆根.乳腺癌中VEGF-D/VEGFR-3与淋巴管生成的关系及临床意义探讨[J].中国组织化学与细胞化学杂志,2015,24(1):85-89.
[14]孙平,刘艳翠,金连锦.乳腺癌组织内VEGFR-3的表达与淋巴结转移的关系[J].现代肿瘤医学,2013,21(6):1234-1236.
[15]杨绍英,刘朝荣,张志刚,等.乳腺癌组织中Survivin、Ki67、VEGFR-3蛋白的表达及意义[J].世界最新医学信息文摘,2016,16(A5):74-75.
[16]Sáinz-Jaspeado M,Claesson-Welsh L.Cytokines regulating lymphangiogenesis[J].Current opinion in immunology,2018(53):58-63.
[17]Deng Y,Zhang X,Simons M.Molecular controls of lymphatic VEGFR3 signaling[J]. Arterioscler Thromb Vasc Biol,2015,35(2)421-429.
[18]Thompson CG,Becker BJ.The impact of multiple endpoint dependency on Q and I(2)in meta-analysis[J]. Research Synthesis Methods,2014,5(3):235-253.
[2]Cedolini C,Bertozzi S,Londero AP,et al.Type of breast cancer diagnosis,screening,and survival[J].Clinical breast cancer,2014,14(4):235-40.
[3]Yeh YW,Cheng CC,Yang ST,et al.Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling[J].Oncotarget,2017,8(3):5603-5618.
[4]Varney ML,Singh RK. VEGF-C-VEGFR3/Flt4 axis regulates mammary tumor growth and metastasis in an autocrine manner[J]. American Journal of Cancer Research,2015,5(2):616-628.
[5]单海琳,邵清. ADAM8和VEGFR-3在乳腺癌中的表达及意义[J].成都医学院学报,2012,7(4):582-585.
[6]宋新峰,路喜安.EGFR VEGFR-3 PDGFRa在三阴乳腺癌中的表达及其临床意义[J].中国药物与临床,2012,12(12):1560-1562.
[7]吴建忠,陈琳,周文斌,等.VEGF受体3在乳腺癌组织中的表达及其意义[J].中国修复重建外科杂志,2013,27(12):1487-1450.
[8]李志刚,黄桂林.青年乳腺癌VEGF-C和VEGFR-3的表达及其与临床病理关系的研究[J].临床和实验医学杂志,2012,11(11):821-822.
[9]刘新兰,黄英,陈萍.人乳腺球蛋白、血管内皮生长因子-C和血管内皮生长因子受体-3在乳腺癌中的表达及其与预后的关系[J].第二军医大学学报,2013,34(10):1078-1082.
[10]刘丽娜.乳腺癌VEGF-C和VEGFR-3表达与淋巴结转移关系[J].中国现代药物应用,2015,9(8):29-30.
[11]王官成,王立军,杨连祥.乳腺癌组织中血管内皮生长因子C、血管内皮生长因子受体3的表达及相关性研究[J].中国煤炭工业医学杂志,2013,16(8):1250-1253.
[12]陈润琦.乳腺癌血管内皮细胞生长因子-C及其受体-3的表达及临床作用[J].中国药物与临床,2013,13(4):496-497.
[13]赵云霞,马琳,蔡兆根.乳腺癌中VEGF-D/VEGFR-3与淋巴管生成的关系及临床意义探讨[J].中国组织化学与细胞化学杂志,2015,24(1):85-89.
[14]孙平,刘艳翠,金连锦.乳腺癌组织内VEGFR-3的表达与淋巴结转移的关系[J].现代肿瘤医学,2013,21(6):1234-1236.
[15]杨绍英,刘朝荣,张志刚,等.乳腺癌组织中Survivin、Ki67、VEGFR-3蛋白的表达及意义[J].世界最新医学信息文摘,2016,16(A5):74-75.
[16]Sáinz-Jaspeado M,Claesson-Welsh L.Cytokines regulating lymphangiogenesis[J].Current opinion in immunology,2018(53):58-63.
[17]Deng Y,Zhang X,Simons M.Molecular controls of lymphatic VEGFR3 signaling[J]. Arterioscler Thromb Vasc Biol,2015,35(2)421-429.
[18]Thompson CG,Becker BJ.The impact of multiple endpoint dependency on Q and I(2)in meta-analysis[J]. Research Synthesis Methods,2014,5(3):235-253.